OPS | Bigg Rec

Résultats : 1 - 10 sur 1,008

Intravenous (IV) aminophylline should not be used as second-line therapy for severe paediatric asthma exacerbations in health care facilities if alternative second-line options are available.

Année: 2026

Institution: World Health Organization

Recommandé contre

Conditionnelle

Certitude des données probantes

Faible

In children and adolescents (aged 0–19 years) with sickle-cell disease (SCD) at risk of recurrent stroke (e.g. history of stroke, haemoglobin S >30% and haemoglobin <9 g/dL), regular blood transfusion with iron chelation therapy is suggested rather than hydroxyurea therapy alone for secondary stroke prevention.

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Très faible

WHO suggests regular changing of the central venous catheter (CVC) administration set (tubing/giving) after administering total parenteral nutrition or lipid products in adults, adolescents, children and neonates. (Short- and long-term catheters) (All population)

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Très faible

If a formal schedule of central venous catheter (CVC) dressing changes is to be used, WHO suggests using dressing change intervals of 3 days or more in adults, adolescents, children and neonates. (Short- and long-term catheters) (All population)

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Très faible

Combination inhaler (steroid plus fast-onset long-acting beta2 agonist) maintenance and reliever therapy (MART) should be considered for children with persistent asthma symptoms requiring regular inhaled corticosteroids (ICS) treatment.

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Modérée

In children and adolescents (aged 0–19 years) with suspected sickle-cell disease (SCD), the use of lateral flow immunoassay and micro-engineered haemoglobin electrophoresis point-ofcare tests (POCTs) is suggested for diagnosis in settings where standard laboratory-based haemoglobin fractionation or DNA-based tests are not available.

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Faible

WHO suggests using a schedule of regular changing of the central venous catheter (CVC) administration set (tubing/giving) every 7 days over other schedules (2, 3, 4 days) when administering routine IV fluids only in adults, adolescents, children and neonates. (Short- and long-term catheters) (All population)

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Faible

WHO suggests not using IV prophylactic antibiotics in adults, adolescents, children and neonates with short- and long-term catheters.(Short- and long-term catheters)

Année: 2026

Institution: World Health Organization

Recommandé contre

Conditionnelle

Certitude des données probantes

Très faible

In children and adolescents (aged 0–19 years) with sickle-cell disease (SCD), the use of opioids alone is suggested for acute pain management rather than paracetamol plus opioids.

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Conditionnelle

Certitude des données probantes

Très faible

Intravenous (IV) short-acting beta2 agonist (SABA) should be used as a potential second-line therapy for severe paediatric asthma exacerbations in addition to standard first-line therapy with inhaled/nebulized medicines (SABA and ipratropium) and systemic corticosteroids in health care facilities.

Année: 2026

Institution: World Health Organization

Recommandé en faveur

Forte

Certitude des données probantes

Élevée